메뉴 건너뛰기




Volumn 15, Issue S3, 2013, Pages 193-196

Targeting inflammation in the treatment of type 2 diabetes

Author keywords

Cytokines; Immunometabolism; Insulin

Indexed keywords

INTERLEUKIN 1;

EID: 84883497939     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12172     Document Type: Review
Times cited : (66)

References (45)
  • 1
    • 0031720795 scopus 로고    scopus 로고
    • Is type II diabetes mellitus a disease of the innate immune system?
    • Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
    • (1998) Diabetologia , vol.41 , pp. 1241-1248
    • Pickup, J.C.1    Crook, M.A.2
  • 2
    • 0030731621 scopus 로고    scopus 로고
    • NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X
    • Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
    • (1997) Diabetologia , vol.40 , pp. 1286-1292
    • Pickup, J.C.1    Mattock, M.B.2    Chusney, G.D.3    Burt, D.4
  • 3
    • 0345700727 scopus 로고    scopus 로고
    • Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study
    • Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
    • (2003) Diabetes , vol.52 , pp. 812-817
    • Spranger, J.1    Kroke, A.2    Mohlig, M.3
  • 4
    • 0035908632 scopus 로고    scopus 로고
    • C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
    • Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
    • (2001) JAMA , vol.286 , pp. 327-334
    • Pradhan, A.D.1    Manson, J.E.2    Rifai, N.3    Buring, J.E.4    Ridker, P.M.5
  • 5
    • 0027459878 scopus 로고
    • Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance
    • Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
    • (1993) Science , vol.259 , pp. 87-91
    • Hotamisligil, G.S.1    Shargill, N.S.2    Spiegelman, B.M.3
  • 6
    • 0036738398 scopus 로고    scopus 로고
    • Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets
    • Maedler K, Sergeev P, Ris F et al. Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
    • (2002) J Clin Invest , vol.110 , pp. 851-860
    • Maedler, K.1    Sergeev, P.2    Ris, F.3
  • 7
    • 0025177196 scopus 로고
    • Elevation of C-reactive protein in active coronary artery disease
    • Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol 1990; 65: 168-172.
    • (1990) Am J Cardiol , vol.65 , pp. 168-172
    • Berk, B.C.1    Weintraub, W.S.2    Alexander, R.W.3
  • 8
    • 40449113524 scopus 로고    scopus 로고
    • The role of inflammatory cytokines in diabetic nephropathy
    • Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
    • (2008) J Am Soc Nephrol , vol.19 , pp. 433-442
    • Navarro-Gonzalez, J.F.1    Mora-Fernandez, C.2
  • 9
    • 34548431826 scopus 로고    scopus 로고
    • Increased number of islet-associated macrophages in type 2 diabetes
    • Ehses JA, Perren A, Eppler E et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
    • (2007) Diabetes , vol.56 , pp. 2356-2370
    • Ehses, J.A.1    Perren, A.2    Eppler, E.3
  • 10
    • 71949118923 scopus 로고    scopus 로고
    • Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I
    • Boni-Schnetzler M, Boller S, Debray S et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-5229.
    • (2009) Endocrinology , vol.150 , pp. 5218-5229
    • Boni-Schnetzler, M.1    Boller, S.2    Debray, S.3
  • 11
    • 77955492173 scopus 로고    scopus 로고
    • Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet
    • Ehses JA, Meier DT, Wueest S et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010; 53: 1795-1806.
    • (2010) Diabetologia , vol.53 , pp. 1795-1806
    • Ehses, J.A.1    Meier, D.T.2    Wueest, S.3
  • 12
    • 75649096002 scopus 로고    scopus 로고
    • Thioredoxin-interacting protein links oxidative stress to inflammasome activation
    • Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
    • (2010) Nat Immunol , vol.11 , pp. 136-140
    • Zhou, R.1    Tardivel, A.2    Thorens, B.3    Choi, I.4    Tschopp, J.5
  • 13
    • 77951800951 scopus 로고    scopus 로고
    • NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
    • Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
    • (2010) Nature , vol.464 , pp. 1357-1361
    • Duewell, P.1    Kono, H.2    Rayner, K.J.3
  • 14
    • 32944468985 scopus 로고    scopus 로고
    • Gout-associated uric acid crystals activate the NALP3 inflammasome
    • Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
    • (2006) Nature , vol.440 , pp. 237-241
    • Martinon, F.1    Petrilli, V.2    Mayor, A.3    Tardivel, A.4    Tschopp, J.5
  • 15
    • 79955038882 scopus 로고    scopus 로고
    • Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling
    • Wen H, Gris D, Lei Y et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
    • (2011) Nat Immunol , vol.12 , pp. 408-415
    • Wen, H.1    Gris, D.2    Lei, Y.3
  • 16
    • 79751512463 scopus 로고    scopus 로고
    • The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
    • Vandanmagsar B, Youm YH, Ravussin A et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
    • (2011) Nat Med , vol.17 , pp. 179-188
    • Vandanmagsar, B.1    Youm, Y.H.2    Ravussin, A.3
  • 17
    • 0029979369 scopus 로고    scopus 로고
    • Biologic basis for interleukin-1 in disease
    • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
    • (1996) Blood , vol.87 , pp. 2095-2147
    • Dinarello, C.A.1
  • 18
    • 77956958947 scopus 로고    scopus 로고
    • Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes
    • Masters SL, Dunne A, Subramanian SL et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
    • (2010) Nat Immunol , vol.11 , pp. 897-904
    • Masters, S.L.1    Dunne, A.2    Subramanian, S.L.3
  • 19
    • 80052650475 scopus 로고    scopus 로고
    • IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction
    • Westwell-Roper C, Dai DL, Soukhatcheva G et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011; 187: 2755-2765.
    • (2011) J Immunol , vol.187 , pp. 2755-2765
    • Westwell-Roper, C.1    Dai, D.L.2    Soukhatcheva, G.3
  • 20
    • 0036720342 scopus 로고    scopus 로고
    • Muscle-derived interleukin-6: mechanisms for activation and possible biological roles
    • Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 2002; 16: 1335-1347.
    • (2002) FASEB J , vol.16 , pp. 1335-1347
    • Febbraio, M.A.1    Pedersen, B.K.2
  • 21
    • 81255157471 scopus 로고    scopus 로고
    • Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
    • Ellingsgaard H, Hauselmann I, Schuler B et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
    • (2011) Nat Med , vol.17 , pp. 1481-1489
    • Ellingsgaard, H.1    Hauselmann, I.2    Schuler, B.3
  • 24
    • 27344441019 scopus 로고    scopus 로고
    • Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes
    • Dominguez H, Storgaard H, Rask-Madsen C et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-525.
    • (2005) J Vasc Res , vol.42 , pp. 517-525
    • Dominguez, H.1    Storgaard, H.2    Rask-Madsen, C.3
  • 25
    • 34547099307 scopus 로고    scopus 로고
    • Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome
    • Lo J, Bernstein LE, Canavan B et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293: E102-109.
    • (2007) Am J Physiol Endocrinol Metab , vol.293
    • Lo, J.1    Bernstein, L.E.2    Canavan, B.3
  • 26
    • 0029906375 scopus 로고    scopus 로고
    • Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM
    • Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
    • (1996) Diabetes , vol.45 , pp. 881-885
    • Ofei, F.1    Hurel, S.2    Newkirk, J.3    Sopwith, M.4    Taylor, R.5
  • 27
    • 0034454915 scopus 로고    scopus 로고
    • No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients
    • Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-1319.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 1316-1319
    • Paquot, N.1    Castillo, M.J.2    Lefebvre, P.J.3    Scheen, A.J.4
  • 28
    • 34247640820 scopus 로고    scopus 로고
    • Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF alpha therapy
    • Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF alpha therapy. Scand J Rheumatol 2007; 36: 91-96.
    • (2007) Scand J Rheumatol , vol.36 , pp. 91-96
    • Rosenvinge, A.1    Krogh-Madsen, R.2    Baslund, B.3    Pedersen, B.K.4
  • 29
    • 17644393196 scopus 로고    scopus 로고
    • Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis
    • Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-766.
    • (2005) Ann Rheum Dis , vol.64 , pp. 765-766
    • Kiortsis, D.N.1    Mavridis, A.K.2    Vasakos, S.3    Nikas, S.N.4    Drosos, A.A.5
  • 30
    • 78650917112 scopus 로고    scopus 로고
    • TNF-α Antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome
    • Stanley TL, Zanni MV, Johnsen S et al. TNF-α Antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E146-150.
    • (2011) J Clin Endocrinol Metab , vol.96
    • Stanley, T.L.1    Zanni, M.V.2    Johnsen, S.3
  • 31
    • 33746445962 scopus 로고    scopus 로고
    • Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation
    • Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 2006; 29: 1712-1713.
    • (2006) Diabetes Care , vol.29 , pp. 1712-1713
    • Yazdani-Biuki, B.1    Mueller, T.2    Brezinschek, H.P.3    Hermann, J.4    Graninger, W.5    Wascher, T.C.6
  • 32
    • 4944258755 scopus 로고    scopus 로고
    • Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab
    • Yazdani-Biuki B, Stelzl H, Brezinschek HP et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004; 34: 641-642.
    • (2004) Eur J Clin Invest , vol.34 , pp. 641-642
    • Yazdani-Biuki, B.1    Stelzl, H.2    Brezinschek, H.P.3
  • 34
    • 34247170807 scopus 로고    scopus 로고
    • Interleukin-1-receptor antagonist in type 2 diabetes mellitus
    • Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
    • (2007) N Engl J Med , vol.356 , pp. 1517-1526
    • Larsen, C.M.1    Faulenbach, M.2    Vaag, A.3
  • 35
    • 84864386088 scopus 로고    scopus 로고
    • Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
    • Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
    • (2012) Diabetes Care , vol.35 , pp. 1654-1662
    • Cavelti-Weder, C.1    Babians-Brunner, A.2    Keller, C.3
  • 36
    • 84873271227 scopus 로고    scopus 로고
    • Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
    • Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1088-1096.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 1088-1096
    • Rissanen, A.1    Howard, C.P.2    Botha, J.3    Thuren, T.4
  • 37
    • 79960086288 scopus 로고    scopus 로고
    • Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study
    • van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 2119-2126.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 2119-2126
    • van Asseldonk, E.J.1    Stienstra, R.2    Koenen, T.B.3    Joosten, L.A.4    Netea, M.G.5    Tack, C.J.6
  • 38
    • 84870619337 scopus 로고    scopus 로고
    • Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial
    • Ridker PM, Howard CP, Walter V et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-2748.
    • (2012) Circulation , vol.126 , pp. 2739-2748
    • Ridker, P.M.1    Howard, C.P.2    Walter, V.3
  • 39
    • 84878774925 scopus 로고    scopus 로고
    • Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes
    • DOI: 10.2337/dc12-1835 [Epub 20 March 2013]
    • Sloan-Lancaster J, Abu-Raddad E, Polzer J et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 2013. DOI: 10.2337/dc12-1835 [Epub 20 March 2013].
    • (2013) Diabetes Care
    • Sloan-Lancaster, J.1    Abu-Raddad, E.2    Polzer, J.3
  • 40
  • 41
    • 64149121817 scopus 로고    scopus 로고
    • Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes
    • Goldfine AB, Silver R, Aldhahi W et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008; 1: 36-43.
    • (2008) Clin Transl Sci , vol.1 , pp. 36-43
    • Goldfine, A.B.1    Silver, R.2    Aldhahi, W.3
  • 42
    • 84876485218 scopus 로고    scopus 로고
    • A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance
    • Goldfine AB, Conlin PR, Halperin F et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013; 56: 714-723.
    • (2013) Diabetologia , vol.56 , pp. 714-723
    • Goldfine, A.B.1    Conlin, P.R.2    Halperin, F.3
  • 43
    • 38949119419 scopus 로고    scopus 로고
    • Salsalate improves glycemia and inflammatory parameters in obese young adults
    • Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31: 289-294.
    • (2008) Diabetes Care , vol.31 , pp. 289-294
    • Fleischman, A.1    Shoelson, S.E.2    Bernier, R.3    Goldfine, A.B.4
  • 44
    • 84872018875 scopus 로고    scopus 로고
    • Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes
    • Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62: 194-204.
    • (2013) Diabetes , vol.62 , pp. 194-204
    • Lee, H.M.1    Kim, J.J.2    Kim, H.J.3    Shong, M.4    Ku, B.J.5    Jo, E.K.6
  • 45
    • 77957652845 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
    • Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 2010; 401: 7-12.
    • (2010) Biochem Biophys Res Commun , vol.401 , pp. 7-12
    • Takasawa, W.1    Ohnuma, K.2    Hatano, R.3    Endo, Y.4    Dang, N.H.5    Morimoto, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.